Rapid Micro Biosystems (RPID) Amortization of Deferred Charges (2020 - 2026)

Rapid Micro Biosystems (RPID) reported Amortization of Deferred Charges of $86000.0 for Q1 2026, up 17.81% sequentially from $73000.0 in Q4 2025.

Rapid Micro Biosystems (RPID) Amortization of Deferred Charges (2020 - 2026) Analysis & Trends

Rapid Micro Biosystems (RPID) has 4 years of Amortization of Deferred Charges data on file, last reported at $86000.0 in Q1 2026.

For the quarter ending Q1 2026, Amortization of Deferred Charges changed N/A year-over-year to $86000.0; the trailing twelve-month figure through Mar 2026 stood at $159000.0 (changed N/A YoY), and the FY2025 full-year result was $97000.0, changed N/A from the prior year.
Amortization of Deferred Charges grew to $86000.0 in Q1 2026, from $73000.0 in the prior quarter.
In the past five years, Amortization of Deferred Charges ranged from a high of $86000.0 in Q1 2026 to a low of $73000.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-
10	Rapid Micro Biosystems	90.41 Mn	80.98 Mn	371,000.00

Download Data